New hope for rare adrenal cancer: radiation before surgery tested
NCT ID NCT06487481
First seen Sep 30, 2025 · Last updated Jun 22, 2026 · Updated 45 times
Summary
This early-phase trial tests giving radiation therapy before surgery to people whose adrenal cancer has come back. The goal is to find a safe dose and see if it helps control the tumor. About 32 adults with resectable recurrent adrenocortical carcinoma will receive daily radiation for 2-3 weeks, then have surgery 4 weeks later. They will be followed for up to 10 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADRENOCORTICAL CARCINOMA (ACC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
radiation therapy (external beam)
What this could lead to
If successful, this approach could improve surgical outcomes and control of recurrent adrenocortical carcinoma, potentially extending survival.
What could go wrong
This is a very early phase 1 trial with only 32 participants, so safety and effectiveness are not yet proven. Radiation and surgery carry risks like tissue damage and complications.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.